nonyl formate | 94247-15-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: nonyl formate
• 英文别名: 1-nonanyl formate；Nonylformiat；Ameisensaeure-nonylester
• CAS: 94247-15-1
• 化学式: C₁₀H₂₀O₂
• mdl: MFCD00046148
• 分子量: 172.268
• InChiKey: MOGJOLMSQWGXPA-UHFFFAOYSA-N

物化性质

• LogP：
  3.943 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  12
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  癸醛 在 葡萄糖 、 glucose dehydrogenase from B_. megaterium 、 nicotinamide adenine dinucleotide phosphate 、 Baeyer–Villiger monooxygenase AFL838 from Aspergillus flavus 作用下， 以 甲醇 为溶剂， 生成 nonyl formate
  参考文献：
  名称：

  真菌Baeyer-Villiger单加氧酶合成烷基甲酸酯

  摘要：

  选择方面：甲酸烷基酯的合成采用Baeyer-Villiger单加氧酶进行。烷基甲酸酯对相应的伯醇产物的区域选择性和自水解的速率受底物浓度影响。

  DOI：

  10.1002/cbic.201600684

文献信息

• Hypervalent λ³-Bromane Strategy for Baeyer−Villiger Oxidation: Selective Transformation of Primary Aliphatic and Aromatic Aldehydes to Formates, Which is Missing in the Classical Baeyer−Villiger Oxidation
  作者：Masahito Ochiai、Akira Yoshimura、Kazunori Miyamoto、Satoko Hayashi、Waro Nakanishi

  DOI：10.1021/ja104330g

  日期：2010.7.14

  undergoes BV rearrangement and produces an ester via facile reductive elimination of an aryl-lambda(3)-bromanyl group, because of the hypernucleofugality. The novel strategy makes it possible to induce selectively the BV rearrangement of straight chain primary aliphatic as well as aromatic aldehydes, which is missing in the classical BVO: for instance, octanal and benzaldehyde afforded rearranged formate

  Baeyer-Villiger 氧化 (BVO) 的概念独特的现代策略被开发出来。我们的新方法涉及将水初始水合为羰基化合物，然后将溴烷 (III) 上的高价芳基-λ(3)-溴烷与所得水合物进行配体交换，从而产生一种新型的活化 Criegee 中间体。由于超核，中间体经历 BV 重排并通过芳基-λ(3)-溴基的轻松还原消除产生酯。这种新策略可以选择性地诱导直链脂肪族和芳香族伯醛的 BV 重排，这在经典 BVO 中是缺失的：例如，辛醛和苯甲醛提供了高选择性（> 95%）的重排甲酸酯我们的条件，而尝试的经典 BVO 仅产生羧酸。这牢固地确立了 BVO 新方法论的强大性质。
• AROMATIC AMINE COMPOUND, CURING AGENT FOR EPOXY COMPOUND, CURABLE COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING CURED PRODUCT, AND METHOD FOR PRODUCING AROMATIC AMINE COMPOUND
  申请人：TOKYO OHKA KOGYO CO., LTD.

  公开号：US20210130284A1

  公开（公告）日：2021-05-06

  An aromatic amine compound capable of satisfactorily forming a cured product having exceptional alkali resistance by reaction with an epoxy compound; a curing agent for an epoxy compound, the curing agent including the aromatic amine compound; a curable composition including the curing agent for an epoxy compound; a cured product of the curable composition; a method for producing the cured product; and a method for producing the abovementioned aromatic amine compound. The aromatic amine compound has a structure such that a specific position in a central skeleton comprising a fused ring such as a fluorene ring is substituted with a side-chain group including two aromatic groups linked by a flexible bond such as an amide bond, at least one amino group is bonded to the end of the side-chain group, and the structure has no hydroxyl groups.

  一种芳香胺化合物，通过与环氧化合物反应能够满意地形成具有异常碱性抗性的固化产品；一种环氧化合物的固化剂，该固化剂包括芳香胺化合物；一种包括环氧化合物的固化剂的可固化组合物；可固化组合物的固化产品；生产所述固化产品的方法；以及生产上述芳香胺化合物的方法。该芳香胺化合物具有这样的结构，即中心骨架中的特定位置包括类似于芴环的融合环，该位置被取代为包括通过柔性键（如酰胺键）连接的两个芳香基的侧链基团，至少一个氨基固定在侧链基团的末端，并且该结构不含羟基。
• CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF
  申请人：Fujifilm Corporation

  公开号：US20210155644A1

  公开（公告）日：2021-05-27

  An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides an anti-adenoviral agent including a compound represented by General Formula [1] (in the formula, R 1 represents a hydrogen atom, a halogen atom, an amino group which may be substituted, a monocyclic nitrogen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a monocyclic nitrogen- and oxygen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; and X represents an oxygen atom or a sulfur atom) or a salt thereof.

  本发明的一个目的是提供一种作为抗腺病毒药剂具有优异药效的化合物，以及一种抗腺病毒药剂。本发明提供了一种包括由通式[1]表示的化合物的抗腺病毒药剂 （在公式中，R 1 表示氢原子、卤素原子、可能被取代的氨基、可能被取代的单环氮含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的单环氮和氧含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的C 1-6 烷氧基、可能被保护的羟基等；R 2 表示氢原子或氨基保护基团；R 3 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；R 4 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；X表示氧原子或硫原子）或其盐。
• HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：US20180098990A1

  公开（公告）日：2018-04-12

  A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells.

  本发明涉及一种具有组蛋白去乙酰化酶抑制活性的4-芳氨基喹唑啉羟胺酸化合物、其制备方法、包含该化合物的药物组合物，以及该化合物和药物组合物在制备组蛋白去乙酰化酶抑制剂药物中的用途。本发明的目的是通过药物设计和合成技术，基于优化4-芳氨基喹唑啉的酶表面识别区域和连接区域，获得一系列具有良好低类型选择性和有利药代动力学特性的选择性组蛋白去乙酰化酶抑制剂，从而在提高正常组织或细胞的抗肿瘤活性的同时，减少对正常组织或细胞的影响。
• Aminoalcohol derivatives
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040006143A1

  公开（公告）日：2004-01-08

  The present invention relates to a compound formula [I]: 1 wherein 2 Y is bond, —O—(CH 2 ) n — (in which n is 1, 2, 3 or 4), etc., Z is cyano, tetrazolyl, etc., R 1 is hydrogen, lower alkyl, etc., R 2 is hydrogen or an amino protective group, R 3 is hydrogen or lower alkyl, R 4 is hydrogen or lower alkyl, R 5 and R 8 are each independently hydrogen, halogen, hydroxy, lower alkyl, etc., R 6 is hydrogen, lower alkyl, etc., R 9 is hydrogen or lower alkyl, and i is 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

  本发明涉及一种化合物公式[I]: 1 其中 2 Y是键，—O—(CH 2 ) n — (其中n是1、2、3或4)，等等， Z是氰基，四唑基，等等， R 1 是氢，低级烷基，等等， R 2 是氢或氨基保护基团， R 3 是氢或低级烷基， R 4 是氢或低级烷基， R 5 和R 8 各自独立是氢，卤素，羟基，低级烷基，等等， R 6 是氢，低级烷基，等等， R 9 是氢或低级烷基，以及 i是1或2， 或其盐。本发明的化合物[I]及其药用可接受的盐对于预防性和/或治疗性治疗尿频或尿失禁是有用的。